Cargando…

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH

PURPOSE: Despite superiority of tamsulosin–dutasteride combination therapy versus monotherapy for lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH), patients at risk of disease progression are often initiated on α-blockers. This study evaluated the impact of initiating tams...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Agate, Salvatore, Wilson, Timothy, Adalig, Burkay, Manyak, Michael, Palacios-Moreno, Juan Manuel, Chavan, Chandrashekhar, Oelke, Matthias, Roehrborn, Claus, Della Pasqua, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994451/ https://www.ncbi.nlm.nih.gov/pubmed/31079189 http://dx.doi.org/10.1007/s00345-019-02783-x

Ejemplares similares

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
por: D’Agate, Salvatore, et al.
Publicado: (2020)

Model‐based meta‐analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms
por: D'Agate, Salvatore, et al.
Publicado: (2020)

Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or severe symptoms
por: D'Agate, Salvatore, et al.
Publicado: (2021)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
por: Roehrborn, C G, et al.
Publicado: (2011)

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study
por: Rosen, Raymond C., et al.
Publicado: (2018)

Current consensus and controversies on male LUTS/BPH (part one)
por: Foo, Keong Tatt
Publicado: (2017)

Current consensus and controversies on male LUTS/BPH (part two)
por: Foo, Keong Tatt
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey
por: Ertel, Phillip, et al.
Publicado: (2016)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors
por: Kolontarev, Konstantin, et al.
Publicado: (2016)

Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients
por: Romano, Federico, et al.
Publicado: (2021)

Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
por: D’Agate, Salvatore, et al.
Publicado: (2020)

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
por: Manohar, Chikka Moga Siddaiah, et al.
Publicado: (2017)

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
por: Alcaraz, Antonio, et al.
Publicado: (2021)

LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations
por: De Nunzio, Cosimo, et al.
Publicado: (2021)

Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis
por: D’Agate, S., et al.
Publicado: (2021)

Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH
por: Liao, Xinyang, et al.
Publicado: (2020)

AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension
por: Xiao, Hengjun, et al.
Publicado: (2016)

WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
por: Kirschner-Hermanns, Ruth, et al.
Publicado: (2019)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands
por: Drake, Marcus J., et al.
Publicado: (2017)

Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?
por: Kaplan, Steven A, et al.
Publicado: (2011)

Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH
por: Wang, Xing-Huan, et al.
Publicado: (2015)

Cluster analysis of men undergoing surgery for BPH/LUTS reveals prominent roles of both bladder outlet obstruction and diminished bladder contractility
por: Schneider, Andrew J., et al.
Publicado: (2021)

Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH
por: Gravas, Stavros, et al.
Publicado: (2009)

Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
por: Zhang, Weiyu, et al.
Publicado: (2019)

Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
por: Alcaraz, Antonio, et al.
Publicado: (2020)

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
por: Woo, Henry H., et al.
Publicado: (2022)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study
por: Alcaraz, Antonio, et al.
Publicado: (2022)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

Relationship among diet habit and lower urinary tract symptoms and sexual function in outpatient-based males with LUTS/BPH: a multiregional and cross-sectional study in China
por: Chen, Yuke, et al.
Publicado: (2016)

Making shared decisions with older men selecting treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH): a pilot randomized trial
por: Ngu, Haidee, et al.
Publicado: (2022)

Tolterodine extended release in the treatment of male oab/storage luts: a systematic review
por: Gacci, Mauro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4opg2d3ngp4k6jjp1dq4ltb5qq